PharmaEssentia Corporation Stock price

Equities

6446

TW0006446008

Biotechnology & Medical Research

End-of-day quote Taiwan S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
320 TWD 0.00% Intraday chart for PharmaEssentia Corporation -2.44% -7.51%
Sales 2024 * 8.39B 263M Sales 2025 * 12.41B 388M Capitalization 106B 3.32B
Net income 2024 * 2.05B 64.17M Net income 2025 * 4.84B 151M EV / Sales 2024 * 10.5 x
Net cash position 2024 * 17.55B 549M Net cash position 2025 * 18.49B 578M EV / Sales 2025 * 7.06 x
P/E ratio 2024 *
46.6 x
P/E ratio 2025 *
19.7 x
Employees 131
Yield 2024 *
-
Yield 2025 *
0.51%
Free-Float 74.34%
More Fundamentals * Assessed data
Dynamic Chart
PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA CI
PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration CI
PharmaEssentia Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
PharmaEssentia Corporation(TWSE:6446) added to Taiwan TAIEX Index CI
Soleno Therapeutics Names Meredith Manning as Chief Commercial Officer MT
PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA CI
PharmaEssentia Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia CI
Pharmaessentia Corporation Enters into Exclusive Global License Agreement with Wuxi Biologics for A Myeloid Immune Checkpoint Antibody Candidate CI
Tranche Update on PharmaEssentia Corporation's Equity Buyback Plan announced on July 28, 2023. CI
PharmaEssentia Corporation's Equity Buyback announced on July 28, 2023, has closed with 4,000,000 shares, representing 1.19% for TWD 1,351.42 million CI
Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B for the Treatment of PV in China CI
PharmaEssentia Corporation(TPEX:6446) added to FTSE All-World Index CI
PharmaEssentia Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
PharmaEssentia Corporation announces an Equity Buyback for 4,000,000 shares, for TWD 8,846.64 million. CI
More news
1 week-2.44%
Current month-2.59%
1 month-1.23%
3 months-7.51%
6 months-4.76%
Current year-7.51%
More quotes
1 week
316.00
Extreme 316
330.00
1 month
316.00
Extreme 316
336.00
Current year
307.50
Extreme 307.5
358.00
1 year
274.00
Extreme 274
446.50
3 years
69.00
Extreme 69
622.00
5 years
53.60
Extreme 53.6
622.00
10 years
45.16
Extreme 45.16
622.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 02-12-31
Director of Finance/CFO - 15-10-13
Chief Tech/Sci/R&D Officer - 22-07-31
Members of the board TitleAgeSince
Director/Board Member 75 14-02-28
Director/Board Member - 06-06-29
Chairman - 03-08-31
More insiders
Date Price Change Volume
24-03-28 320 0.00% 495,771
24-03-27 320 +0.63% 915,897
24-03-26 318 -2.30% 1,410,543
24-03-25 325.5 -0.15% 467,845
24-03-22 326 -0.61% 498,681

End-of-day quote Taiwan S.E., March 27, 2024

More quotes
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Company's products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
320 TWD
Average target price
417.2 TWD
Spread / Average Target
+30.39%
Consensus
  1. Stock
  2. Equities
  3. Stock PharmaEssentia Corporation - Taiwan S.E.